###begin article-title 0
###xml 51 59 <span type="species:ncbi:9606">Patients</span>
Elevated Peripheral Visfatin Levels in Narcoleptic Patients
###end article-title 0
###begin p 1
Conceived and designed the experiments: ND. Performed the experiments: NM AE. Analyzed the data: NM JH AE. Contributed reagents/materials/analysis tools: PBM TF AP. Wrote the paper: ND NM AE.
###end p 1
###begin title 2
Objective
###end title 2
###begin p 3
###xml 519 527 <span type="species:ncbi:9606">patients</span>
Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 36 44 <span type="species:ncbi:9606">patients</span>
For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the International Classification of Sleep Disorders were examined (BMI mean 30.3+/-5.5, age mean 52.5+/-16.1 years). As a control group 39 unrelated (n = 12 males and n = 27 females) healthy volunteers with no sleep disorder according to DSM-IV were included (BMI mean 28.5+/-4.6, age mean 51.1+/-13.6 years). Peripheral visfatin levels were measured using a commercial enzyme immunoassay kit with a measurement range from 0.1-1000 ng/ml. Narcolepsy symptoms, severity and frequency of symptoms as well as the total duration of various aspects of the symptomatology were assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Circulating visfatin was found to be significantly increased in HLA DR2 positive narcoleptic patients compared to controls.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Taken together, our results add to the evidence of disturbed immunological regulation in patients with narcolepsy.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 103 106 103 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Aldrich1">[1]</xref>
###xml 302 305 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Aldrich1">[1]</xref>
###xml 378 381 378 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Dahmen1">[2]</xref>
###xml 383 386 383 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Schuld1">[3]</xref>
###xml 522 525 522 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Aldrich1">[1]</xref>
###xml 663 666 663 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Chemelli1">[4]</xref>
###xml 707 710 707 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Lin1">[5]</xref>
###xml 870 873 870 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Nishino1">[6]</xref>
###xml 875 878 875 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Nishino2">[7]</xref>
###xml 880 883 880 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Higuchi1">[8]</xref>
###xml 1412 1415 1412 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Mignot1">[9]</xref>
###xml 1417 1421 1417 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Rogers1">[10]</xref>
###xml 1578 1582 1578 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Dauvilliers1">[11]</xref>
###xml 1845 1849 1845 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Black1">[12]</xref>
###xml 1851 1855 1851 1855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-MartnezRodrguez1">[13]</xref>
###xml 2035 2039 2031 2035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Vgontzas1">[14]</xref>
###xml 2267 2271 2263 2267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-HinzeSelch1">[15]</xref>
###xml 2464 2468 2452 2456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Okun1">[16]</xref>
###xml 2641 2645 2625 2629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Himmerich1">[17]</xref>
###xml 2871 2875 2855 2859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Hohjoh1">[18]</xref>
###xml 2877 2881 2861 2865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Hohjoh2">[19]</xref>
###xml 2883 2887 2867 2871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Wieczorek1">[20]</xref>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 658 662 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 863 869 <span type="species:ncbi:9606">humans</span>
###xml 1569 1577 <span type="species:ncbi:9606">patients</span>
###xml 2355 2363 <span type="species:ncbi:9606">patients</span>
Narcolepsy is a sleep disorder that affects approximately 0.05% of the population in Western countries [1]. Typical symptoms include day time somnolence, cataplexies (emotionally triggered, sudden, involuntary loss of muscle tone), sleep related hallucinations, sleep paralysis, and automatic behavior [1]. In addition, narcoleptic patients are more obese than healthy controls [2], [3]. On a physiological level, the disorder has been conceptualized as a disturbance in the regulation of sleep, REM sleep and wake cycles [1]. Recently, abnormalities in the orexin neurotransmitter system have been shown to cause narcolepsy-like symptoms in orexin-knockout mice [4] as well as in narcoleptic canine breeds [5]. Furthermore, a deficiency in orexin levels was found in the liquor cerebro spinalis and to a much lesser extent in the peripheral blood of narcoleptic humans [6], [7], [8]. Orexinergic neurons originate from the lateral hypothalamus and reach out to most parts of the central nervous system including the brain stem. Orexin plays a crucial role in regulating and maintaining sleep/wakefulness states and energy homeostasis. In most cases, however, narcolepsy is not associated with abnormalities of orexinergic genes, and the cause(s) of narcolepsy are still not fully understood. However, narcolepsy is strongly associated with the major histocompatibility class II haplotype HLA DRB1*1501-QB1*0602 [9], [10]. Clinical trials using intravenous immunoglobulin infusions in recent onset narcolepsy with cataplexy have led to improvement in cataplexy in some patients [11]. Despite the fact that specific antibody markers for narcolepsy are still elusive, an autoimmune-mediated mechanism is considered the most probable etiology for narcolepsy and the elucidation of immune markers is one of the top priorities in narcolepsy research [12], [13]. A number of studies have focused on cytokines. Vgontzas et al., 1997, reported elevated TNF-alpha plasma in narcoleptics based on the analysis of 11 narcoleptics and 10 controls [14]. Hinze-Selch, in an attempt of replication in nine narcoleptics and controls reported in 1998 that mitogen-stimulated monocytes of narcoleptics secreted more IL-6 than control monocytes, whereas no TNF abnormalities were found [15]. Okun et al., 2004, measured plasma levels of TNF-alpha and IL-6 in 39 narcoleptic patients and in 40 controls and confirmed significantly higher TNF-alpha and IL-6 levels in the narcoleptics [16]. Himmerich et al., 2006 measured TNF-alpha and its soluble receptor in 30 narcoleptics and 120 controls and found elevated levels of the TNF-receptor but not of TNF itself [17]. Indirect support for an involvement of cytokines in the pathophysiology of narcolepsy comes from a number of molecular genetic studies, including one of our own group in which variants of TNF were associated with narcolepsy [18], [19], [20].
###end p 11
###begin p 12
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Fukuhara1">[21]</xref>
###xml 492 496 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Fukuhara1">[21]</xref>
###xml 649 653 649 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Moschen1">[22]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Okun1">[16]</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Himmerich1">[17]</xref>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Rajala1">[23]</xref>
###xml 906 910 906 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Tilg1">[24]</xref>
###xml 1225 1229 1225 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Pftzner1">[25]</xref>
###xml 487 491 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 633 638 <span type="species:ncbi:9606">human</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
Fukuhara et al. (2005) identified a molecule that is expressed at much higher levels in visceral fat than in subcutaneous fat [21]. This molecule, denoted visfatin to indicate its abundance in visceral fat, turned out to have been already identified as a growth factor for early B cells called pre-B cell colony-enhancing factor (PBEF), a 52-kilodalton cytokine also expressed in lymphocytes. Visfatin exerts insulin-mimetic effects in cultured cells and lowers plasma glucose levels in mice [21]. Visfatin dose-dependently upregulates the production of the pro- and anti-inflammatory cytokines IL-1, IL-1Ra, IL-6, IL-10, and TNF in human monocytes [22]. These cytokines play a substantial role in a wide range of infectious and inflammatory diseases including narcolepsy [16], [17], [23]. Visfatin has been linked to several inflammatory disease states such as acute lung injury and rheumatoide arthritis [24]. In addition, Visfatin is considered to be a putative biomarker for metabolic syndrome. However, therapeutic intervention with drugs known to alter insulin resistance and dyslipidemia did not result in any change in circulating visfatin levels in non-diabetic patients with elevated risk for macrovascular disease [25]. The role of visfatin in the pathophysiology of the metabolic syndrome is still under investigation.
###end p 12
###begin p 13
###xml 129 137 <span type="species:ncbi:9606">patients</span>
To test the hypothesis that visfatin levels are altered in narcoleptics we compared peripheral visfatin levels of 54 narcoleptic patients with those of 39 controls.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Thorpy1">[26]</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 319 327 <span type="species:ncbi:9606">Patients</span>
###xml 494 501 <span type="species:ncbi:9606">patient</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 1167 1175 <span type="species:ncbi:9606">Patients</span>
###xml 1709 1717 <span type="species:ncbi:9606">patients</span>
###xml 1805 1813 <span type="species:ncbi:9606">patients</span>
###xml 2015 2023 <span type="species:ncbi:9606">patients</span>
This study is part of a broader effort to clinically and genetically characterize narcolepsy patients. For the present analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the International Classification of Sleep Disorders [26] were examined. Patients were all unrelated and were either from the Department of Psychiatry, Mainz, or recruited with the help of the Deutsche Narkolepsie-Gesellschaft, a nationwide German patient organization. Most narcoleptic patients visited our department to participate in the research program. Others who were unable or unwilling to come but eager to participate were visited by a member of the research team at home. Total duration of narcolepsy symptoms, severity of daytime sleepiness and frequency (0 = more than a year ago, 1 = within the past year, 2 = within the past month, 3 = within the past week, 4 = within the past 24 hours) of the symptoms cataplexies, automatic behaviour, hallucinations and sleep paralysis were assessed by unstructured and structured clinical interviews in including the Stanford Center for Narcolepsy Sleep Inventory (). Patients were only enrolled into the study when unambiguous cataplexies in addition to severe daytime sleepiness were reported and when sleep laboratory confirmation of the diagnosis was present in the medical records. To exclude symptomatic narcolepsies, the medical history was assessed and a neurologic examination was performed. As a control group 39 unrelated (n = 12 males and n = 27 females) healthy volunteers with no sleep disorder according to DSM-IV were included. In order to maximise similarities in lifestyle and habits between patients and controls controls were either spouses or genetically unrelated aquaintances of the patients. Absence of narcolepsy or other major sleep disorders was checked by clinical interview and by the administration of the Stanford Center for Narcolepsy Sleep Inventory. Blood samples were collected in patients and controls after a 12-hour fasting period in the morning between 8:00 and 10:00 am. Samples were immediately centrifuged, cooled with dry ice and stored at -80degreesC until the visfatin measurements. An additional anticoagulated blood smple was taken for DNA preparation (HLA-testing).
###end p 16
###begin p 17
###xml 315 322 315 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002980-t001">table 1</xref>
###xml 4 16 <span type="species:ncbi:9606">participants</span>
###xml 47 59 <span type="species:ncbi:9606">participants</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
All participants were of Caucasian origin. All participants gave written, informed consent. No participation fees were paid. The study design was approved by the local Ethics Committee of the Federal Chamber of Physicians of Rhineland-Palatinate. For a general characterisation of patients and controls, please see table 1.
###end p 17
###begin title 18
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Characterisation of patients and controls.
###end title 18
###begin p 19
n.s. = not significant; n.a. = not applicable or not measured
###end p 19
###begin title 20
Measurements
###end title 20
###begin p 21
Visfatin levels were measured using an enzyme immunoassay kit from Phoenix Pharmaceuticals (Phoenix Europe GmbH, Karlsruhe, Germany) with a measurement range from 0.1-1000 ng/ml. This enzyme immunoassay kit is designed to detect a specific peptide and its related peptides based on the principle of "competitive" enzyme immunoassay.
###end p 21
###begin p 22
The detection range was 0.1-1000 ng/ml with an inter-assay variation of less than 14% and intra-assay variation less than 5% according to the manufacturer.
###end p 22
###begin p 23
The unknown concentration in samples can be determined by extrapolation to the standard curve.
###end p 23
###begin p 24
###xml 4 12 <span type="species:ncbi:9606">Patients</span>
All Patients and controls were HLA typed by standard PCR-SSO using a commercial kit (Dynal RELI SSO HLA-DRB1 Test; Invitrogen GmbH, Karlsruhe, Germany).
###end p 24
###begin title 25
Statistical Analysis
###end title 25
###begin p 26
Descriptive results of continous variables are expressed as means+/-SD for Gaussian variables and as median and interquartile range for non-Gaussian variables. Group differences were tested with the Mann-Whitney-U-Test and the Kruskal-Wallis-Test. For the assessment of correlations, Spearman correlation coefficients were calculated. All analyses were two-tailed and conducted with SPSS software (version 12.0 for Windows). P-values of p<0.05 were considered to be statistically significant.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Mean visfatin concentrations were elevated in narcoleptic patients in comparison to age and BMI matched controls. The median was 33.7 ng/ml in narcoleptics (interquartile range 19.7-54.4) vs. 19.4 ng/ml in the controls (interquartile range 15.3-31.5; p = 0.036).
###end p 28
###begin p 29
###xml 39 44 <span type="species:ncbi:9606">women</span>
###xml 49 52 <span type="species:ncbi:9606">men</span>
###xml 73 78 <span type="species:ncbi:9606">women</span>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 174 177 <span type="species:ncbi:9606">men</span>
###xml 437 442 <span type="species:ncbi:9606">women</span>
###xml 455 460 <span type="species:ncbi:9606">women</span>
Visfatin values did not differ between women and men. The median for all women (narcoleptic patients and controls) was 26.1 ng/ml (interquartile range 15.3-50.4) and for all men was 25.5 ng/ml (interquartile range 17.3-58.3; p = 0.642). The visfatin values for the female narcoleptics were 38.3 ng/ml (interquartile range 20.7-54.8) and 27.9 ng/ml for the narcoleptic males (interquartile range 17.3-58.4; p = 0.582) and for the control women 19.4 ng/ml (women, interquartile range 14.7-28.4) and 21.2 ng/ml for the male controls (interquartile range 17.4-68.6; p = 0.327).
###end p 29
###begin p 30
###xml 504 512 500 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002980-g001">figure 1</xref>
Closer examination of the data revealed that the group difference between narcoleptics and controls was mainly driven by the HLA DR2 positive narcoleptics (BMI 31.1+/-5.1; p = 0.51 compared to controls; age 54.2+/-16.2; p = 0.23 compared to controls). The median of the HLA DR2 positive narcoleptics was 36.2 ng/ml (interquartile range 21.0-57.5) vs. 20.2 ng/ml in HLA-neg. narcoleptics (interquartile range 12.6-35.2; p = 0.036) vs. 19.4 ng/ml in the controls (interquartile range 15.3-31.5; p = 0.010; figure 1). No differences between HLA positive and negative controls were apparent. The median of the HLA DR2 positive controls was 19.4 ng/ml (interquartile range 12.7-40.8) vs. 20.4 ng/ml in HLA-neg. controls (interquartile range 16.0-36.1; p = 0.756).
###end p 30
###begin title 31
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Boxplot comparing controls with narcoleptics, outliers above 100 ng/ml (one individual of the control group, five narcoleptic patients) are not depicted.
###end title 31
###begin p 32
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 106 109 <span type="species:ncbi:9606">men</span>
###xml 114 119 <span type="species:ncbi:9606">women</span>
###xml 145 150 <span type="species:ncbi:9606">women</span>
###xml 223 226 <span type="species:ncbi:9606">men</span>
###xml 310 315 <span type="species:ncbi:9606">woman</span>
###xml 387 390 <span type="species:ncbi:9606">men</span>
After the stratification in HLA DR2 positive and negative patients, there was again no difference between men and women: The median for HLA-pos. women was 44.2 ng/ml (interquartile range 25.1-57.5). The median for HLA-pos. men was 27.9 ng/ml (interquartile range 17.3-95.9; p = 0.321). The median for HLA-neg. woman was 17.7 ng/ml (interquartile range 8.9-28.9). The median for HLA-neg. men was 29.5 ng/ml (interquartile range 20.0-39.1; p = 0.643).
###end p 32
###begin p 33
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
Visfatin was not correlated with age or BMI, neither in the HLA DR2 positive narcoleptic patients (age: corr. coeff. 0.062, p = 0.684; BMI: corr. coeff. 0.044, p = 0.772), in the HLA DR2 negative naroleptic patients (age: corr. coeff. 0.238, p = 0.570; BMI: corr. coeff. 0.204, p = 0.629) nor in the control group (age: corr. coeff. 0.316, p = 0.050; BMI: corr. coeff. -0.155, p = 0.346).
###end p 33
###begin p 34
###xml 547 554 547 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002980-t002">table 2</xref>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
Finally, we calculated correlations between visfatin levels and different measures of the frequency and severity of narcoleptic symptoms, with the age of onset, the BMI and the duration of narcolepsy. Unexpectedly, we found a sifgnificant correlation between the self-reported frequency of cataplexies and visfatin levels in the HLA-DR2 positive male narcoleptics, but not in the HLA DR2 positive female narcoleptics. All other correlations, including those calculated with the HLA DR2 negative patients (data not shown) were non-significant (see table 2).
###end p 34
###begin title 35
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Correlations between visfatin levels of HLA-pos. narcoleptic patients and clinical findings.
###end title 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Mignot2">[27]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Black1">[12]</xref>
###xml 883 887 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Hector1">[28]</xref>
###xml 1093 1097 1089 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Moschen1">[22]</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
In our analyses, visfatin levels were significantly higher in HLA DR2 positive narcoleptic patients than in BMI- and age-matched controls. This result corroborates previous findings, that different measures of immunological activity are elevated in narcoleptics. A link between narcolepsy and altered immune functions has been hypothesized ever since the tight association between narcolepsy and the HLA-system had been recognized (for an excellent review see Mignot et al., 1995 [27] and Black 2005 [12]). The TNF-alpha system is of additional specific interest because it directly interacts with the visfatin system. By incubating fat tissue with TNF, Hector et al., 2007, demonstrated that TNF is a strong inductor of visfatin mRNA secretion and thus it appears conceivable that elevated TNF levels in narcoleptic patients contribute to the elevated visfatin in the present study [28]. On the other hand, visfatin is able to stimulate secretion of different cytokines such as interleukin beta, TNF and Il-6 and thus is considered immunomodulating and proinflammatory (Moschen et al., 2007) [22].
###end p 37
###begin p 38
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Wurtmann1">[29]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Otero1">[30]</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-LopezBermejo1">[31]</xref>
###xml 958 962 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Pilz1">[32]</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Guzik1">[33]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 128 133 <span type="species:ncbi:9606">human</span>
Human narcolepsy may have multiple etiologies and may develop at least partially on a genetic background. The high incidence of human leukocyte antigen (HLA)-DR2 haplotypes among narcoleptics suggests that an autoimmune process is involved in the pathophysiology of the disease. A relationship between narcolepsy and a deficiency of the peptide neurotransmitter orexin (hypocretin) has been established [29]. One hypothesis is that narcolepsy is an autoimmunologic disease that leads to the specific degeneration of hypothalamic hypocretin-containing cells. The observation of increased visfatin levels in narcoleptics is in good accordance with this thesis, because elevated levels of visfatin were also found in other autoimmune diseases such as as rheumatoid arthritis [30] and diabetes type I [31]. Moreover, elevated visfatin has been found in conditions that involve acute immunological activation such as colorectal cancer and acute lung injury (ALI) [32], [33].
###end p 38
###begin p 39
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Mignot3">[34]</xref>
###xml 723 727 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Mignot3">[34]</xref>
###xml 785 789 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Mignot2">[27]</xref>
###xml 967 971 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Wieczorek1">[20]</xref>
###xml 973 977 973 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Berndt1">[35]</xref>
###xml 979 983 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Dogru1">[36]</xref>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Dogru2">[37]</xref>
###xml 991 995 991 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Varma1">[38]</xref>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Marcinkowska1">[39]</xref>
###xml 1003 1007 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Chan1">[40]</xref>
###xml 1457 1461 1457 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002980-Dauvilliers2">[41]</xref>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
In our study, the elevation of visfatin was only found in HLA DR2 positive narcoleptics, who constitute the vast majority of all cases, but not in HLA DR2 negative patients, whose visfatin levels were not distinguishable from the visfatin levels of the controls. This observation fits excellently in the theroretical framework described above because it is mainly the HLA DR2 positive patients who show diminished orexin levels whereas HLA DR2 negative patients tend to display orexin levels comparable to those of controls [34]. Accordingly, the autoimmune hypothesis of narcolepsy might be true only for the HLA DR2 positive or the central orexin deficient form. Therefore, the visfatin results support existing evidence [34], including molecular genetic evidence from our own group [27] that HLA DR2 positive and negative narcolepsy may represent different pathophysiological entitites leading to a common clinical appearance. In our study, as in previous studies [20], [35], [36], [37], [38], [39], [40], there was no correlation between age, BMI or gender and visfatin levels. The finding of a correlation between visfatin levels and frequencies of cataplexies in male but not female HLA DR2 positive patients was rather unexpected. Currently, we can not offer an evidentiary explanation. However, the issue of sexual dimorphisms in narcolepsy has previously been raised in the context of potentially cataplexy relevant neurotransmitter metabolisation [41].
###end p 39
###begin p 40
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
In summary, our study adds to the growing evidence of subtle signs of immunological dysfunction in narcoleptic patients. Because our study is the first study measuring visfatin in narcoleptic patients, independent replication is necessary before considering the findings conclusive.
###end p 40
###begin p 41
We greatly appreciate the work of Mirjam Lobig and her team at IKFE laboratory in performing visfatin determinations. We also wish to thank W.E. Hitzler and A. Jung from the University of Mainz Transfusion Center for HLA-Typing. This work contains parts of the doctoral thesis of N.M. The work was supported by DFG DA 370/4-1.
###end p 41
###begin title 42
References
###end title 42
###begin article-title 43
Narcolepsy.
###end article-title 43
###begin article-title 44
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Increased prevalence of obesity in narcoleptic patients and relatives.
###end article-title 44
###begin article-title 45
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Increased body-mass index in patients with narcolepsy.
###end article-title 45
###begin article-title 46
###xml 30 34 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
###end article-title 46
###begin article-title 47
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
###end article-title 47
###begin article-title 48
###xml 34 39 <span type="species:ncbi:9606">human</span>
Hypocretin (orexin) deficiency in human narcolepsy.
###end article-title 48
###begin article-title 49
###xml 78 83 <span type="species:ncbi:9606">human</span>
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.
###end article-title 49
###begin article-title 50
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Plasma orexin-A is lower in patients with narcolepsy.
###end article-title 50
###begin article-title 51
###xml 62 70 <span type="species:ncbi:9606">patients</span>
HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.
###end article-title 51
###begin article-title 52
###xml 63 71 <span type="species:ncbi:9606">patients</span>
HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy.
###end article-title 52
###begin article-title 53
Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.
###end article-title 53
###begin article-title 54
Narcolepsy: a review of evidence for autoimmune diathesis.
###end article-title 54
###begin article-title 55
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Comparative analysis of patients with narcolepsy-cataplexy, narcolepsy without cataplexy and idiopathic hypersomnia.
###end article-title 55
###begin article-title 56
Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders.
###end article-title 56
###begin article-title 57
###xml 41 49 <span type="species:ncbi:9606">patients</span>
In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls.
###end article-title 57
###begin article-title 58
Exploring the cytokine and endocrine involvement in narcolepsy.
###end article-title 58
###begin article-title 59
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Plasma levels of tumor necrosis factor alpha and soluble tumor necrosis factor receptors in patients with narcolepsy.
###end article-title 59
###begin article-title 60
###xml 82 87 <span type="species:ncbi:9606">human</span>
Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy.
###end article-title 60
###begin article-title 61
###xml 126 131 <span type="species:ncbi:9606">human</span>
Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy.
###end article-title 61
###begin article-title 62
TNFA promoter polymorphisms and narcolepsy.
###end article-title 62
###begin article-title 63
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
###end article-title 63
###begin article-title 64
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
###end article-title 64
###begin article-title 65
Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis.
###end article-title 65
###begin article-title 66
Adipocytokines: mediators linking adipose tissue, inflammation and immunity.
###end article-title 66
###begin article-title 67
###xml 128 136 <span type="species:ncbi:9606">Patients</span>
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk-Results from the PIOSTAT Study.
###end article-title 67
###begin article-title 68
ICSD-International classification of sleep disorders: Diagnostic and coding manual.
###end article-title 68
###begin article-title 69
Narcolepsy and immunity.
###end article-title 69
###begin article-title 70
###xml 52 57 <span type="species:ncbi:9606">human</span>
TNF-alpha alters visfatin and adiponectin levels in human fat.
###end article-title 70
###begin article-title 71
Narcolepsy and the hypocretins.
###end article-title 71
###begin article-title 72
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.
###end article-title 72
###begin article-title 73
Serum visfatin increases with progressive beta-cell deterioration.
###end article-title 73
###begin article-title 74
Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.
###end article-title 74
###begin article-title 75
Adipocytokines - novel link between inflammation and vascular function?
###end article-title 75
###begin article-title 76
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
###end article-title 76
###begin article-title 77
###xml 73 79 <span type="species:ncbi:9606">humans</span>
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
###end article-title 77
###begin article-title 78
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.
###end article-title 78
###begin article-title 79
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
###end article-title 80
###begin article-title 81
###xml 136 142 <span type="species:ncbi:9606">humans</span>
Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.
###end article-title 81
###begin article-title 82
###xml 44 49 <span type="species:ncbi:9606">women</span>
Increased plasma visfatin concentrations in women with polycystic ovary syndrome.
###end article-title 82
###begin article-title 83
MAO-A and COMT polymorphisms and gene effects in narcolepsy.
###end article-title 83
###begin p 84
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 84
###begin p 85
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The authors have no support or funding to report.
###end p 85

